OCUL vs. COLL, XNCR, PRTA, ABCL, MIRM, DCPH, CNTA, IMNM, MNKD, and KNSA
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Collegium Pharmaceutical (COLL), Xencor (XNCR), Prothena (PRTA), AbCellera Biologics (ABCL), Mirum Pharmaceuticals (MIRM), Deciphera Pharmaceuticals (DCPH), Centessa Pharmaceuticals (CNTA), Immunome (IMNM), MannKind (MNKD), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical preparations" industry.
Ocular Therapeutix (NASDAQ:OCUL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, community ranking, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Ocular Therapeutix has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Collegium Pharmaceutical has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical has a net margin of 8.50% compared to Ocular Therapeutix's net margin of -138.15%. Collegium Pharmaceutical's return on equity of 107.39% beat Ocular Therapeutix's return on equity.
59.2% of Ocular Therapeutix shares are owned by institutional investors. 5.5% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 4.0% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Ocular Therapeutix received 49 more outperform votes than Collegium Pharmaceutical when rated by MarketBeat users. Likewise, 69.74% of users gave Ocular Therapeutix an outperform vote while only 65.33% of users gave Collegium Pharmaceutical an outperform vote.
In the previous week, Ocular Therapeutix had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 7 mentions for Ocular Therapeutix and 5 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.30 beat Ocular Therapeutix's score of 0.29 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.
Ocular Therapeutix currently has a consensus price target of $17.60, suggesting a potential upside of 270.92%. Collegium Pharmaceutical has a consensus price target of $39.00, suggesting a potential upside of 7.08%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than Collegium Pharmaceutical.
Summary
Ocular Therapeutix beats Collegium Pharmaceutical on 10 of the 18 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
